Epidemiological Features and Clinical Course of COVID -19 Infection in Cancer Patients: The Rovid Study

October 31, 2023 updated by: Istituto Oncologico Veneto IRCCS

Epidemiological Features and Clinical Course of SARS-CoV-2 Infection in Cancer Patients Within the Veneto Oncology Network: the ROVID Study

The study aims to retrospectively collect epidemiological and clinical data in patients with solid tumors and SARS Covid2 infections belonging to oncology centers within the Veneto Oncology Network

Study Overview

Status

Completed

Conditions

Detailed Description

The aim of this study is to create a Veneto Oncology Network with the aim of collecting clinical and epidemiological data of cancer Patients affected by SAR- Covid-2 infection over a period of 1 year. Descriptive statistical approaches will be used to process the data.

The aim is to evaluate the development rate of severe clinical forms of infection in patients with SARS-Cov-2 and the possible association with tumour characteristics and treatment.

In addition, the results of serological tests can be compared with the outcome of the diagnostic swabs and the clinical evolution of the infection in order to obtain more information regarding the significance of specific antibody development.

Study Type

Observational

Enrollment (Actual)

761

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

  • Italy
      • Belluno, Italy
        • Aulss1 Dolomiti
      • Padova, Italy
        • Istituto Oncologico Veneto -UOC Oncologia 1
    • PD
      • Padova, PD, Italy
        • istituto Oncologico Veneto -UOSD Melanoma

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

18 years to 65 years (Adult, Older Adult)

Accepts Healthy Volunteers

No

Sampling Method

Non-Probability Sample

Study Population

Cancer patients with SAR COV-2 infection within the Veneto Oncology Network

Description

Inclusion Criteria:

  • be 18 Years and older
  • cancer patients belonging to Veneto 's Oncological Network
  • Patients with SAR COV-2 infection

Exclusion Criteria:

  • Patients with no SAR COV2 Infection
  • Volunteers
  • No Cancer Patients

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

Cohorts and Interventions

Group / Cohort
Cancer Patients with SARS-COV-2 infection.

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Time Frame
The rate of SAR-COV2 infection development in association with tumor characteristics.
Time Frame: through study completion, an average of 18 months.
through study completion, an average of 18 months.

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Istituto Oncologico Veneto IRCCS

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

June 4, 2020

Primary Completion (Actual)

June 4, 2021

Study Completion (Actual)

June 4, 2021

Study Registration Dates

First Submitted

March 19, 2021

First Submitted That Met QC Criteria

March 22, 2021

First Posted (Actual)

March 23, 2021

Study Record Updates

Last Update Posted (Actual)

November 1, 2023

Last Update Submitted That Met QC Criteria

October 31, 2023

Last Verified

October 1, 2023

More Information

Terms related to this study

Additional Relevant MeSH Terms

Other Study ID Numbers

  • Rovid

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Subscribe